Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)

Inclusion Criteria: 1. Adults aged 19 years or older who have been diagnosed with multidrug resistant pulmonary tuberculosis 2. Adults prescribed MDR-END regimen according to the Korean Guidelines for Tuberculosis after being informed of this study from the investigator and signing an informed consent form Exclusion Criteria: 1. Patients with confirmed quinolone resistance 2. Patients with hypersensitivity to one or more of the following drugs: Delamanid, Linezolid, Levofloxacin, and Pyrazinamide 3. Patients who are found to have contraindications according to the approved labels of Delamanid, Linezolid, Levofloxacin, or Pyrazinamide 4. Patients with or with a history of optic neuritis or peripheral neuritis 5. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 6. Pregnant or lactating women 7. Women of childbearing potential who are unwilling to use appropriate contraception during the study treatment